CD19 and acute lymphoblastic leukemia: After CD19-targeted therapy, 10–30% of the patients show CD19-negative BCP-ALL cells at relapse [57,58,59], and these CD19-negative cells are resistant to CD19-directed CAR-T cell therapies [108].